From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany. DJennings@indd.org. From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.